Sign In
Buy JNJ
$256.35
+0.530 (+0.207%)
At Close: Jul 31, 2026
Inside J&J's Lab to Create a Simpler Robotic Surgery Device
08:00am, Sunday, 02'nd Aug 2026
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race
3 Dividend Stocks to Buy Before August Ends and Hold Forever
07:00am, Sunday, 02'nd Aug 2026
August has a habit of humbling investors. The VIX sits at 17.09, well off the March 2026 peak of 31.05, but the pattern is familiar: quiet summer tape, thin liquidity, and a single headline that can s
Axiom Investment Management LLC Acquires New Holdings in Johnson & Johnson $JNJ
05:24am, Saturday, 01'st Aug 2026
Axiom Investment Management LLC acquired a new stake in Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 3,832 shar
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
03:29pm, Friday, 31'st Jul 2026
Abbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences. Johnson & Johnson maintains superior net margins an
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
02:19pm, Friday, 31'st Jul 2026
Johnson & Johnson (NYSE:JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
10:55am, Friday, 31'st Jul 2026
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
Things are going well for the pharmaceutical giant.
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
11:31am, Thursday, 30'th Jul 2026
Johnson & Johnson (NYSE:JNJ) is significantly expanding its biotechnology portfolio with two major deals, securing a $1 billion acquisition of Firefly Bio Inc. and forging a strategic partnership with
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Thursday, 30'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patient
Nasdaq rebounds hard as Microsoft, Apple and chipmakers rally
07:05am, Thursday, 30'th Jul 2026
11:00am: Economy slowing This morning's weaker-than-expected GDP data could raise concerns that the economy is slowing more quickly than anticipated, says...
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
06:13pm, Wednesday, 29'th Jul 2026
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
05:42pm, Wednesday, 29'th Jul 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary
Johnson & Johnson lowers 2026 profit forecast
05:38pm, Wednesday, 29'th Jul 2026
Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership w
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CA
